Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies 1 . After surgery, patients with estrogen receptor (ERa)-positive breast cancer are treated with adjuvant endocrine therapy 2 , including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs) 3 . However, more than 20% of patients relapse within 10 years and eventually progress to incurable metastatic disease 4 . Here we demonstrate that the choice of therapy has a fundamental influence on the genetic landscape of relapsed diseases. We found that 21.5% of AI-treated, relapsed patients had acquired CYP19A1 (encoding aromatase) amplification (CYP19A1 amp ). Relapsed patients also developed numerous mutations targeting key breast cancer-associated genes, including ESR1 and CYP19A1. Notably, CYP19A1 amp cells also emerged in vitro, but only in AI-resistant models. CYP19A1 amplification caused increased aromatase activity and estrogen-independent ERa binding to target genes, resulting in CYP19A1 amp cells showing decreased sensitivity to AI treatment. These data suggest that AI treatment itself selects for acquired CYP19A1 amp and promotes local autocrine estrogen signaling in AI-resistant metastatic patients.
ERα activation characterizes more than 70% of breast cancers, where it represents the key prognostic factor and therapeutic target 5 . ERα activation is primarily dependent on circulating estrogens and results in genome-wide chromatin binding at thousands of regulatory regions 6 . ERα binding leads to the transcription of hundreds of genes central to breast cancer growth 6 . Endocrine therapies, including SERMs and AIs, were developed to prevent ERα activation and block breast cancer growth 5 . The mechanisms behind drug resistance are only partially understood and often involve transcriptional activation of alternative survival pathways, especially at later stages of the disease 7 . Nonetheless, recent genomic studies highlight how ERα signaling might still have a role in metastatic disease. For example, activating somatic mutations targeting ESR1 (the gene encoding ERα) are found at higher frequencies after endocrine therapy 8, 9 . These mutations have been characterized in metastatic lesions from patients that received several cycles of endocrine therapy and chemotherapy 10, 11 , suggesting that the selective pressure imposed by endocrine treatments might favor the development of focused genetic aberrations during tumor evolution 11 . However, it is impossible to infer from most studies when genetic aberrations originate and how they are selected, because patients are biopsied after multiple treatments. The SERM tamoxifen (TAM) directly blocks ERα coactivation in the tumor cell, whereas AI targets CYP19A1 (aromatase) in the peripheral tissue, thereby lowering estrogen availability. We recently reported that ERα-positive breast cancer cells activate alternative epigenetic programs in response to TAM or AI 12 , suggesting that choice of endocrine therapies might affect tumor evolution. Here we examine, in parallel, a cohort of ERα-positive patients who were treated with single-agent adjuvant endocrine therapies (TAM or nonsteroidal AI) and re-biopsied when they had their first distal relapse ( Fig. 1a and Supplementary Figs. 1 and 2) .
We initially assessed copy number alterations (CNAs) of the genes encoding the targets of AI and TAM (CYP19A1 (15q21) and ESR1 (6q25), respectively), considering the central role of copy number Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer l e t t e r s l e t t e r s changes in breast cancer 13 . Meta-analysis of data from primary, treatment-naive patients using GISTIC-based 14 cBioPortal 15 showed that CYP19A1 and ESR1 CNAs are exceedingly rare in ERα-positive primary breast cancers (0.006%, 2/321 for CYP19A1 and 0.018%, 6/321 for ESR1 in ERα-positive primary breast cancer, based on The Cancer Genome Atlas (TCGA) CNAs data 16 ; threshold = 1.5-fold change). Using an independent database of SNP-array-based studies with an alternative CNA algorithm 17 , we confirmed the rarity of CYP19A1 amplification events ( Supplementary Table 1 ). CYP19A1 and ESR1 amplification are rare in other primary cancers as well ( Supplementary Fig. 3 and Supplementary Table 1 ). These data demonstrate that CYP19A1 and ESR1 loci are not rearrangement hot spots in untreated primary cancers. We then analyzed our discovery cohort consisting of tumor samples collected from the first relapse after single therapy using a TaqMan CNA assay, comparing metastatic with matched normal breast tissue. Notably, we found that the CYP19A1 locus is amplified (CYP19A1 amp ) in 6/37 (16%) of patients that received AI. Conversely, only one patient (3%) that received TAM showed evidence of CYP19A1 amp (Fig. 1a) .
The ESR1 locus was also substantially amplified in material from relapsed patients (24% and 13%, AI-and TAM-treated cohorts, respectively) ( Fig. 1a) . To confirm these data, we investigated an independent validation cohort with similar clinical characteristics.
In agreement with the discovery cohort, we found that CYP19A1 was amplified in 6/19 (32%) of AI-treated patients and only 1/19 (5%) of TAM-treated patients ( Fig. 1b) . ESR1 was amplified in 4/19 (21%) of AI-treated and 0/19 of the TAM-treated relapse samples ( Supplementary Fig. 4a ). The CYP19A1 locus showed evidence for both focal and chromosome-wide amplification ( Supplementary  Fig. 5a ). CYP19A1 and ESR1 CNAs might work cooperatively, considering the rate of coamplification in AI-treated patients (8/12 CYP19A1 amp patients also carried ESR1 amp ; Supplementary Fig. 5b) .
Notably, we also identified CYP19A1 and ESR1 amplification in patient-derived xenografts (PDXs) from patients previously treated with nonsteroidal AI ( Fig. 1c and Supplementary Fig. 4b ).
Collectively, these data show that treatment with reversible AI significantly increased the frequency of CYP19A1 amp at first distal relapse (21.5% versus 4%, AI versus TAM, P = 0.009, P = 0.004 including PDXs, two-tailed Fisher's exact test). Similarly, we observed a trend in AI-treated patients of preferential amplification of the ESR1 locus (23% versus 8%, AI versus TAM, P = 0.06, P = 0.03 including PDXs, two-tailed Fisher's exact test). CYP19A and ESR1 amplification in distal relapses from AI-resistant breast cancers is strongly reminiscent of androgen receptor (AR) amplification in patients with castrationresistant prostate cancer 18, 19 . We next designed a DNA-FISH assay to validate CYP19A1 amplification and investigate its degree of heterogeneity. We examined four cases that were found to be amplified by TaqMan; all of them present strong evidence for cluster amplification ( Fig. 2a,b ). FISH analysis also confirmed 100% of TaqMan calls in the validation data set ( Supplementary Fig. 6 ). More than 90% of nuclei from each of the metastatic samples examined by FISH have CYP19A1 amplification signals, indicating that CYP19A1 amp cells represent the dominant clone. Additionally, the ratio of the tandemly repeated centromeric 15 α-satellite to CYP19A1 strongly suggests that CYP19A1 amplification is not a consequence of unspecific aneuploidy (Fig. 2b) . Using DNA-FISH, we did not find convincing evidence of CYP19A1 amplification in the respective primary samples ( Fig. 2a) . Therefore, these results support the notion that CYP19A1 amplification occurs under treatment, although we cannot exclude the presence of very small CYP19A1 amp subclones at diagnosis.
We then investigated the frequency of metastasis-specific ESR1 activating mutations 11 and other commonly occurring mutations 13, 16 (in PIK3CA, MAPK, TP53 and GATA3) in AI-or TAM-treated distal relapses compared to matched normal germline DNA using an AmpliSeq custom panel for targeted sequencing (Supplementary Table 2 and Online Methods). Overall, we found similar patterns of mutations between the two cohorts ( Fig. 2c and Supplementary Data 1 and 2). These patterns, however, may be different from those previously characterized in primary breast cancers ( Supplementary Fig. 7) . For example, we identified several novel ESR1 mutations, including predicted activating mutations encoding p.Leu536His 20 (patient ID TAM 19T), p.Met543Ala 21 (AI 28T and AI 46T) p.Asp538Ala (TAM 10T) and p.Arg503Gln (AI 28T and AI 39T) ( Fig. 2c,d and Supplementary Data 1 and 2), in addition to the common p.Tyr537Ser (AI 36T). These mutations occur at relatively high allele frequencies and can be polyclonal (AI 28T) ( Supplementary Fig. 8a ). In addition, we identified several truncating TP53 mutations (encoding, for example, p.Arg213* (AI 8T), p.Cys242* (AI 13T) and p.Glu294* (TAM 23T); Fig. 2c,d and Supplementary Data 1 and 2). Most of these mutations were confirmed by a second assay ( Supplementary Fig. 8b) . Notably, we designed probes against CYP19A1 and identified the novel recurrent alteration p.Pro410Ser/Leu (AI 5T and 18T; Supplementary Fig. 8b Tamoxifen AI Sample not available Not mutated
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ERα activating SNVs
ERα potential activating SNVs TP53 truncating l e t t e r s and Supplementary Data 2). This alteration was mutually exclusive with CYP19A1 amplification, further suggesting its functional significance ( Supplementary Fig. 8b) . Interestingly, Pro410 might be involved in the formation of a functional channel 22 . Collectively, these data demonstrate that several metastasis-specific mutations might have a role in early tumor progression. In postmenopausal women, aromatase inhibitors target the peripheral conversion of testosterone or androstenedione to estrogens by inhibiting aromatase. Cholesterol is the common precursor of sex hormones, including testosterone and androstenedione, the two substrates of the aromatase enzyme 23 . In vitro, AI-resistant cells develop de novo cholesterol biosynthesis via epigenetic events to promote autonomous ERα activation 12 . Current treatment protocols can effectively remove all estradiol from serum used in culture, but they are far less efficient in removing testosterone 24 . Thus, we hypothesized that CYP19A1 amplification might favor autocrine estrogen production starting from epigenetically driven de novo cholesterol biosynthesis or residual male hormones. We investigated the possibility of some CNAs contributing to AI resistance using a shallow whole-genome sequencing approach 25 to profile several cell lines derived from ERαpositive breast cancer MCF7 cells and exposed to distinct endocrine treatments 12, 26 (Supplementary Fig. 9a ). Among those, LTED cells are derived upon chronic estrogen deprivation 26, 27 , mimicking AItreated breast cancer. Genomic analysis suggests that all endocrineresistant cells maintain DNA rearrangements of parental MCF7 cells (3p13-p14 and 20q12-qter gains). However, LTED cells also acquired CNAs around the CYP19A1 locus ( Supplementary Fig. 9b ). CYP19A1 CNAs were identified in LTED cells but not in tamoxifen-fulvestrant-resistant models (Supplementary Fig. 9b ). We next quantified CYP19A1 CNAs using our TaqMan assay ( Fig. 3a) and DNA-FISH ( Fig. 3b) . Notably, the degree of amplification was comparable to that observed in AI-treated patients in vivo ( Figs. 1c and 3a) . We could not identify a single CYP19A1 amp cell among MCF7 cells, suggesting that CYP19A1 CNAs were acquired during treatment. Compared to parental MCF7 cells, LTED cells undergo a tenfold increase in ERα protein levels 12 , although we did not find significant evidence for ESR1 amplification or ERα activating mutations. Collectively, these data indicate that estrogen deprivation promotes CYP19A1 CNAs in vitro similarly to AI treatment in vivo. CYP19A1 amp LTED cells have higher levels of both CYP19A1 mRNA and CYP19A1 protein than MCF7 cells carrying wild-type CYP19A1 (CYP19A1 WT ) ( Fig. 3c-e ). Single-cell RNA-FISH (Online Methods) showed a large degree of heterogeneity in CYP19A1 expression; however, CYP19A1 amp cells had a significantly higher chance of accumulating more CYP19A1 mRNA molecules per cell (Fig. 3e) . We also found that LTED cells had significantly higher aromatase activity than MCF7 cells, and this could be partially antagonized with AI (P < 0.05, one-way ANOVA with Tukey's post-test; Supplementary Fig. 10a ). CYP19A1 amp LTED cells, but not CYP19A1 WT MCF7 cells, showed significant transcriptional activation of three well-characterized estrogen target genes 7 (TFF1, EGR3 and CA12) in response to androstenedione (Fig. 3f) . More notably, transcriptional activation by androstenedione could be partially blocked by AI (letrozole) (Fig. 3f) . These data indicate that acquired CYP19A1 amplification drives increased endogenous aromatase activity and promotes estrogen-independent transcription.
When we investigated genome-wide ERα binding to target genes in MCF7 and LTED cells in the absence of estrogens, we found that the chromatin of LTED cells was strongly enriched in ERα binding l e t t e r s compared to parental MCF7 cells (Fig. 4a) , which is consistent with our transcriptional data. As expected, MCF7 cells grown in the presence of estrogen were not sensitive to AI (Fig. 4b) , whereas CYP19A1 amp LTED cells had low sensitivity (half-maximal inhibitory concentration (IC 50 ) = 80 µM; Fig. 4c) . To test the role of CYP19A1 amp on AI sensitivity, we then treated LTED cells and parental MCF7 cells with two independent small interfering RNAs (siRNAs) targeting CYP19A1 and measured cell viability in response to the AI letrozole ( Fig. 4b-d and Supplementary Fig. 10b ). siRNAs against CYP19A1 significantly increased sensitivity to AI treatment in CYP19A1 amp LTED cells (Fig. 4d) but did not affect MCF7 cells grown in estrogensupplemented conditions ( Fig. 4e and Supplementary Fig. 10c) . CYP19A1 overexpression did not confer a growth advantage to MCF7 cells grown in the presence of estradiol. However, CYP19A1 overexpression was sufficient to relieve cell cycle arrest in MCF7 cells cultured in absence of estrogens. Notably, this effect was not antagonized by letrozole (Fig. 4e) . Finally, we confirmed that ERα still has a role in CYP19A1 amp LTED cell growth, as shown by LTED cell sensitivity to fulvestrant treatment (Supplementary Fig. 10d ). Moreover, our results in CYP19A1 amp LTED cells treated with an irreversible AI (exemestane) suggested that increased aromatase activity can be antagonized with a steroidal AI (Fig. 4f) . Collectively, these data support our initial hypothesis and suggest that CYP19A1 amplification might induce reduced sensitivity to reversible AI treatment. CYP19A1 amplification triggers ERα activity by converting male sex hormones obtained through endogenous epigenetic cholesterol biosynthesis 12 or circulating within the tumor microenvironment. In vivo and in vitro data indicate that CYP19A1 CNAs are acquired rather than selected. Indeed, LTED cells develop CYP19A1 CNAs over the course of chronic estrogen deprivation (>1 year). We then analyzed the time to first relapse, merging our AI patient data sets. Relapses characterized by CYP19A1 CNAs emerged significantly later than those with wild-type CYP19A1 (median 57 versus 30 months, amplified versus wild-type P = 0.0112, log-rank Mantel-Cox test; Fig. 4g) . These data support the notion that breast cancer cells treated with AI slowly evolve to create a favorable autocrine microenvironment through genetic and epigenetic reprogramming (Fig. 4h) . One unexplained clinical observation is that patients progressing under reversible AI treatment (letrozole or anastrozole) occasionally respond to irreversible AI (i.e., exemestane). Notably, five CYP19A1 amp AItreated patients in our study showed stabilized disease for ~1 year, on average, after switching to exemestane (Supplementary Figs. 1 and  2) . Thus, it is tempting to speculate that CYP19A1 amplification might arise in response to reversible inhibitors but could be antagonized by switching to irreversible inhibitors. Alternatively, it should be clinically feasible to directly antagonize the low levels of circulating male hormones commonly found in postmenopausal women. Considering that AI normally targets peripheral tissues, our data also warrant AI pharmacodynamics studies to evaluate the ability of this class of drugs to target tumor cells directly. Taken together, our clinical data demonstrate that the evolution of breast cancer is shaped by clinical intervention and thus advocate the development of treatmentand setting-specific biomarkers.
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oNLINE METHodS
Adjuvant setting patient selection and tissue preparation. The IEO Data Quality Control Unit selected from the institutional database a set of consecutive breast cancer patients fulfilling the following criteria: (i) tumors classified as luminal A-like and luminal B-like (HER2 negative), in accordance with St. Gallen 2013 recommendations 28 ; (ii) patients receiving exclusively AIs (50 patients) or TAM (50 patients) as systemic adjuvant therapy; (iii) patients with at least 1 year of follow up; (iv) patients who experienced a distant metastasis as first event after surgery and upon adjuvant therapy. Patients who initially presented with bilateral breast tumors, were receiving neoadjuvant treatments or had metastatic breast disease at the time of presentation or within 12 months after surgery were excluded. The initial data set used for this project comprised 26,495 women who had undergone surgery for a first primary breast cancer at the IEO between 1994 and 2014. All the cases prospectively entered the IEO breast cancer database and were discussed at the weekly multidisciplinary meeting. Patients had follow-up physical examinations every 6 months, annual mammography and breast ultrasounds, blood tests every 6-12 months and further evaluations when symptomatic. Data on the patients' medical history, concurrent diseases, surgery, pathological evaluation, results of staging procedures, radiotherapy, adjuvant systemic treatments, events occurring during the follow up and treatments for metastatic disease were available. Use of patients' data was approved by the ethics committee of the IEO and by the Italian Data Protection Authority. All patients provided written informed consent. All the primary tumors were fresh sampled, fixed in 4% buffered formalin and embedded in paraffin. All the metastatic biopsies were fixed in 4% buffered formalin. Detailed information regarding tumor type and grade, ER/PgR and HER2 status and Ki-67 labeling index were available in all the cases of primary and metastatic tumors. ER/PgR and HER2 immunoreactivity was assessed in line with the clinical practice procedures applicable at diagnosis. HER2 immunoreactivity was assessed using the monoclonal antibody CB11 (Novocastra, 1:800) from 1995 until 2005, and the HercepTest (Dako) thereafter. Cases classified as HER2 + by immunohistochemistry were tested by FISH analysis with Vysis probes, in accordance with the ASCO/CAP guidelines. Ki-67 labeling index was assessed with the Mib-1 monoclonal antibody (Dako, 1:200) by counting at least 500 invasive tumor cells independently of their staining intensity and without focusing on hot spots. Only tumors classified as luminal A-like (ER-and PgR-positive, absence of HER2 overexpression and Ki-67 <20%) and luminal B-like (ER-positive, HER2-negative and at least one of Ki-67 ≥20% and PgR <20%) in accordance with St. Gallen recommendations were included in the study 28 . All the samples (primary tumors and paired metastatic deposits) from the patients satisfying the aforementioned criteria were reviewed at the IEO Division of Pathology (University of Milan) for assessing tumor cellularity and for tumor enrichment by macrodissection, if necessary. DNA from all the samples was extracted using commercially available kits (QIAmp DNA FFPE Tissue Kit, Qiagen), and the DNA yield was measured by Qubit Fluorometric Quantitation (Thermo Fisher Scientific). Finally, two 3-µm thick slides were cut from all the samples and put on charged slides for FISH analysis.
DNA extraction and TaqMan assay.
For tumor samples, hematoxylin-and eosin-stained sections were prepared assessing the percentage of tumor cells and evaluated by a pathologist. Samples with less than 80% tumor cells were microdissected to increase the percentage of tumor cells. Matched normal DNA was extracted from nonmetastatic axillary lymph nodes or histologically non-neoplastic breast samples obtained from mammary quadrants macroscopically free of disease. Genomic DNA from FFPE tissue sections was extracted using QIAamp FFPE Tissue kit (Qiagen) according to the manufacturer's instructions. TaqMan Copy Number Assay (Applied Biosystems) for CYP19A1 (Hs00116110_cn) and ESR1 (Hs02488982_cn) was performed using the 7900HT Fast Real-Time PCR Systems (Applied Biosystems) according to the manufacturer's protocol. TERT, RNAse P (RPPH1), and GARBR3 genes were analyzed as endogenous reference genes (Applied Biosystems, 4458373, 4403326 and hs_05365082_cn). Copy number (CN) for each sample was estimated using the Copy Caller Software V1.0 (Applied Biosystems) using the matched normal counterpart as reference. CN range bars indicated the minimum and maximum CN calculated for the sample replicates.
Targeted sequencing and in silico analysis. An AmpliSeq custom panel was designed using Ion AmpliSeq Designer 2.2 (http://www.ampliseq.com/) against the exons of TP53, ESR1, PIK3CA, GATA3, MAP3K1 and CYP19A1. For the preliminary analysis, we filtered the design taking into consideration previously identified mutations (COSMIC, 141 amplicons, Supplementary  Table 2 ). For the validation replicate, we then included the entire set of exons (184 amplicons). Libraries were generated from 10 ng DNA (tumor and normal) using the Ion AmpliSeq Library Kit v2.0 (Life Technologies) according to the manufacturer's instructions. Quantification of the libraries was performed using the Quant-iT dsDNA HS assay kit and a Qubit2.0 fluorimeter (Life Technologies). Templates were prepared from a pool of equimolar amounts of each library using the Ion PGM Template OT2 200 Kit with OneTouch2 system (Life Technologies). Samples were sequenced on the Ion Torrent PGM sequencer using the Ion PGM 200 Sequencing Kit v2.0 on Ion 318 chips. Data were analyzed using IonReporter and MuTect 29 to compare metastatic samples with normal DNA (normal breast samples extracted from the same patient).
Fluorescence in situ hybridization (FISH) analysis. FISH co-hybridization using a specific clone covering the altered locus and the specific α-satellite, as control probe for ploidy status, was performed on formalin-fixed paraffin embedded sections. Specifically, RP11-66L23 BAC clone for the CYP19A1 locus at 15q21.2 (red signal) and 15 α-satellite probe (green signal) were used to identify CYP19A1 gene amplification. The BAC clone was selected using the University of California Santa Cruz Genome Browser Database (http:// genome.ucsc.edu/) and was tested on normal human metaphase cells to verify the absence of cross-hybridization, while the α-satellite probes were kindly provided by M. Rocchi (University of Bari, Italy). FISH experiments were performed as previously described, with minor modifications 30 . An average 30 representative nuclei scored per sample, scanning several areas to account for potential heterogeneity was counted to calculate the amplification ratio.
Single cell RNA-FISH. The protocol for adherent mammalian cell lines was optimized for Stellaris FISH probes. Hybridization was performed overnight, and no anti-fade was used for imaging. The sequence of the CAL Fluor Red 590 tagged probe targeting the CYP19A1 mRNA is provided in the Supplementary Note. Samples were imaged using a Nikon Ti-E scanning laser confocal inverted microscope (A1) with 60× oil objective in tandem with Nikon NIS-Elements imaging software. Excitation was by 561.5-nm diode-pumped solid state. Detection was via 595/50-nm filter. Optical sections were captured at 0.300-µm intervals and a resolution of 256 by 256 pixels and zoom factor of 6.8, resulting in a voxel size of 0.0047 µm 3 (0.1243 µm by 0.1243 µm by 0.3 µm). Four times averaging was used to reduce photon and camera noise. An automated spot-count algorithm determined the number of mRNAs 31 . For the analysis, we included 30 positive-control cells to better define an mRNA spot.
Cell lines and hormone manipulation.
Parental MCF7 breast cancer cell lines were maintained in DMEM containing 10% FCS. MCF7 cells and derivatives were authenticated using STR profiling. Cells were routinely tested for Mycoplasma contamination. The chronically estrogen-deprived MCF7-derived LTED breast cancer cell lines were maintained in phenol-red free DMEM containing 10% charcoal-stripped FCS (SFCS). Both media were supplemented with 2 mM l-glutamine and 100 units/mL penicillin 0.1 mg/mL. Estradiol 10 −8 M (E2758 Sigma-Aldrich) was added routinely to MCF7. Both cell lines were starved for 48 h before further treatment. Subsequently, both cell lines were treated with 10 −8 M estradiol or androstenedione (25 nM final concentration). LTED cells were also treated in the presence or absence of the aromatase inhibitor letrozole (100 nM final concentration). After 24 h, cells were lysed and RNA extracted with RNAeasy Micro Kit (Qiagen) according to the manufacturer's instructions. The quantity, quality and integrity of isolated mRNA were confirmed by absorption measurement and RNA gel electrophoresis. Then, 1 µg RNA was retrotranscribed by using iSCRIPT (Bio-Rad) containing random hexamers. Afterwards, quantitative real-time PCR was carried out using SYBR select master mix (Life Technologies), and expression of ERα targets (TFF1, EGR3 and CA12) assessed. Values were quantified using the comparative threshold cycle method, and target gene mRNA expression was normalized to GAPDH. Primers are available upon request. Results are expressed as means ± s.e.m. One-way ANOVA statistical analysis was performed using GraphPad Prism, and with GraphPad Software (GraphPad Software, Inc.). Two-sided P < 0.05 was considered statistically significant and are expressed as *P < 0.05. For CYP19A1 protein quantification, we used the Abcam ab71264 antibody. siRNAs for CYP19A1 were obtained from Thermo Fisher (siSilencer Select prevalidated s3875 and s3877). siRNA was transfected at 5 nM final concentration 2 d before SRB analysis (day 0). SRB proliferation measurements were obtained after 3 further days of culture in the presence of increasing amount of letrozole. Experiments were conducted using 5 technical replicates and 3 independent biological replicates. CYP19A1-overexpressing cells were obtained by transfecting MCF7 cells with full-length CYP19A1 (RC205890, OriGene Technologies) and selection using G418. SRB proliferation experiments were conducted as described above. For the exemestane challenge, MCF7 and LTED cells were plated in identical numbers and then treated with increased dose of exemestane (Tocris BioScience). SRB proliferation experiments were conducted as described above.
